Table 1.
Minimum inhibitory concentrations (MIC) of E. coli isolate KOEC3 and transformants for various antimicrobials (µg/ml)
| Antimicrobials | KOEC3 | Transformed E. coli DH5α (with blaNDM-5 insert) |
|---|---|---|
| Amikacin | >32 | ≤8 |
| Gentamicin | >8 | ≤1 |
| Tobramycin | >8 | ≤1 |
| Imipenem | >8 | ≤1 |
| Meropenem | >8 | ≤1 |
| Doripenem | >8 | ≤1 |
| Faropenem | >16 | ≤1 |
| Ertapenem | >8 | ≤0.5 |
| Cefazolin | >16 | >16 |
| Cefuroxime | >16 | 8 |
| Ceftazidime | >16 | ≤0.5 |
| Ceftriaxone | >32 | ≤2 |
| Cefepime | >16 | ≤1 |
| Aztreonam | >16 | ≤2 |
| Ampicillin | >16 | >16 |
| Amoxicillin-Clavulanatea | >16/8 | >16/8 |
| Piperacillin-Tazobactamb | >64/4 | >64/4 |
| Trimethoprim-sulfamethoxazole | >2/38c | ≤0.5/9.5d |
| Nitrofurantoin | 32 | ≤16 |
| Ciprofloxacin | >2 | ≤0.5 |
| Levofloxacin | >4 | ≤1 |
| Moxifloxacin | >4 | ≤1 |
| Tetracycline | ≤2 | ≤2 |
aAmoxicillin (16 µg/ml) and clavulanate (8 µg/ml) in combination
bPiperacillin (64 µg/ml) and tazobactam (4 µg/ml) in combination
cTrimethoprim (2 µg/ml) and sulfamethoxazole (38 µg/ml) in combination
dTrimethoprim (0.5 µg/ml) and sulfamethoxazole (9.5 µg/ml) in combination